Chemotherapy Decisions and Patient Experience With the Recurrence Score Assay for Early-Stage Breast Cancer
Chemotherapy Decisions and Patient Experience With the Recurrence Score Assay for Early-Stage Breast Cancer
复制标题
DOI：
10.1002/cncr.30324
复制
发表时间：
2017-01-01
期刊：
影响因子：
6.2
通讯作者：
Katz, Steven J.
中科院分区：
文献类型：
--
作者：
Friese, Christopher R.;Li, Yun;Katz, Steven J.
背景：21-基因复发评分（RS）分析根据复发风险对早期雌激素受体阳性乳腺癌进行分层。很少有研究检查医生使用RS推荐辅助全身化疗或患者的测试和决策经验的方式。方法：这项研究调查了2013 - 2014年接受乳腺癌治疗的3880名女性;她们是从洛杉矶县和格鲁吉亚监测、流行病学和最终结果登记处确定的（应答率，71%）。女性报告化疗建议，化疗的接收，测试的经验，并决定满意度。登记处将肿瘤数据、RS和调查联系起来。回归模型检查与RS和亚组的化疗建议和接收相关的因素。研究结果：有1527例I/II期、雌激素受体/孕激素受体阳性、人表皮生长因子2阴性的患者：778例接受了RS（62.6%的淋巴结阴性、疾病良好的患者，24.3%的淋巴结阴性、疾病不良的患者，13.0%的淋巴结阳性的患者; P
BACKGROUND: The 21-gene recurrence score (RS) assay stratifies early-stage, estrogen receptor-positive breast cancer by recurrence risk. Few studies have examined the ways in which physicians use the RS to recommend adjuvant systemic chemotherapy or patients' experiences with testing and decision making. METHODS: This study surveyed 3880 women treated for breast cancer in 2013-2014; they were identified from the Los Angeles County and Georgia Surveillance, Epidemiology, and End Results registries (response rate, 71%). Women reported chemotherapy recommendations, the receipt of chemotherapy, testing experiences, and decision satisfaction. Registries linked the tumor data, RS, and surveys. Regression models examined factors associated with chemotherapy recommendations and receipt by the RS and subgroups. RESULTS: There were 1527 patients with stage I/II, estrogen receptor/progesterone receptor-positive, human epidermal growth factor 2-negative disease: 778 received an RS (62.6% of patients with node-negative, favorable disease, 24.3% of patients with node-negative, unfavorable disease, and 13.0% of patients with node-positive disease; P